<DOC>
	<DOCNO>NCT02508168</DOCNO>
	<brief_summary>The purpose study determine relative bioavailability alogliptin 12.5 milligram ( mg ) immediate-release metformin 1000 mg administer individual tablet fixed-dose combination ( FDC ) product .</brief_summary>
	<brief_title>Phase 1 Bioavailability Study SYR-322MET</brief_title>
	<detailed_description>The drug test study call SYR-322MET ( alogliptin 12.5 mg metformin 1000 mg FDC tablet ) . SYR-322MET tested ass whether pharmacokinetic property ( process body ) affect administer FDC compare administration alogliptin metformin alone . This study look lab result people take SYR-322MET . This crossover study enroll approximately 24 participant . Participants randomly assign ( chance , like flip coin ) one two treatment sequence . All participant receive treatment two period ; order receipt determine randomization code . All participant receive follow study medication end study : - Alogliptin 12.5 mg + Metformin 1000 mg individual tablet - SYR-322MET ( alogliptin 12.5 mg metformin 1000 mg fixed-dose combination [ FDC ] tablet ) This single center trial conduct Russia . The overall time participate study 63 day . Participants make multiple visit clinic include two 4-day period confinement clinic , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure include request participant fast laboratory evaluation . 3 . Is healthy male female . 4 . Is age 18 55 year , inclusive , time informed consent first study medication dose . 5 . Weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.5 30.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . Exclusion Criteria 1 . Has receive investigational compound within 30 day prior Checkin ( Day1 ) . 2 . Has receive alogliptin metformin hydrochloride ( HCl ) previous clinical study therapeutic agent within 90 day prior Checkin ( Day1 ) . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 4 . Has clinically significant history current diagnosis cardiovascular , respiratory , neurological , endocrine , hematopoietic , immune , urinary , genital , gastrointestinal , hepatic psychiatric disease . 5 . Has fast blood glucose low 3.88 millimoles per liter ( mmol/L ) 6 . Has experience acute infectious disease within 4 week screen . 7 . Has history clinically significant allergic reaction know hypersensitivity component formulation alogliptin , metformin related compound . 8 . Has positive urine drug result drug abuse ( define illicit drug use ) positive alcohol breath test Screening Checkin ( Day 1 ) . 9 . Consumes 10 drink weekly ( 1 drink equivalent 0.5 liter beer , 200 milliliter [ mL ] dry wine 50 mL hard liquor ) history alcoholism , drug and/or substance abuse . 10 . Has take exclude medication , supplement , food product time period list Excluded Medications Dietary Products table , include intake medicine pronounce effect blood circulation , liver function ( barbiturate , omeprazole , cimetidine , etc . ) within 2 month Day 1 Period 1 . 11 . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 12 . If male , participant intend donate sperm course study 12 week last dose study medication . 13 . If female , subject unprotected sex nonsterilized men within 30 day IMP administration . 14 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention . 15 . Has nonstandard diet ( example , vegetarian vegan ) lifestyle ( include nighttime work , extreme physical activity weight lift ) , may interfere trial . 16 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 Period 1 . 17 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody syphilis screening . 18 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin Day 1 . Cotinine test positive Screening Checkin ( Day 1 ) . 19 . Has poor peripheral venous access . 20 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 30 day prior Day 1 Period 1 . 21 . Has abnormality routine physician examination , laboratory and/or ECG find 22 . Has systolic blood pressure great ( &gt; ) 130 millimeter mercury ( mm Hg ) less ( &lt; ) 100 mm Hg , diastolic blood pressure &gt; 90 mm Hg &lt; 70 mm Hg ; heart rate &lt; 60 bpm &gt; 80 bpm screening ( Day 28 Day 2 ) checkin Period 1 ( Day 1 ) . 23 . Has participate clinical study within 3 month Day 1 Period 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>